Stay updated on Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.

Latest updates to the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page revision was updated from v3.6.5 to v3.6.6, indicating a newer version of the MARIPOSA-2 study page.SummaryDifference0.0%

- Check15 days agoChange DetectedA new entry '2023 ( U.S. NIH Grant/Contract )' was added to the study's identifiers, updating the record's funding metadata.SummaryDifference0.0%

- Check22 days agoChange DetectedThe study timeline metadata was updated, with two date entries added and two removed, affecting milestone and update timestamps shown on the study record.SummaryDifference0.1%

- Check29 days agoChange DetectedRevision 3.6.5 has been added, replacing 3.6.4, indicating a minor update to the page's metadata/versioning rather than user-visible content.SummaryDifference0.0%

- Check36 days agoChange DetectedThe page’s revision history has been updated with new update dates (2026-07-30, 2028-03-01, 2026-07-02, 2026-07). Some older dates have been removed (2026-06-08, 2027-11-30, 2026-06-04, 2026-06).SummaryDifference0.1%

- Check50 days agoChange DetectedThe page revision tag was updated from v3.6.3 to v3.6.4, signaling a content update to the study details page.SummaryDifference0.0%

Stay in the know with updates to Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.